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AbsTRACT
Peripartum cardiomyopathy (PPCM) is a rare form of 
pregnancy-associated heart failure and is considered 
to be a diagnosis of exclusion. There are many 
hypotheses on the aetiology of PPCM; however, the 
exact pathophysiological mechanism remains unknown. 
It shows many resemblances to other conditions, such 
as familial dilated cardiomyopathy or myocarditis, and 
therefore it can be hard to make a definite diagnosis. 
We describe four cases of peripartum-onset heart failure 
in women who were suspected of having PPCM. We 
discuss the differential diagnosis, pathophysiological 
mechanisms and various diagnostic modalities.
InTRoduCTIon
Peripartum cardiomyopathy (PPCM) is a rare form 
of pregnancy-associated heart failure and is consid-
ered to be a diagnosis of exclusion. Currently, the 
Heart Failure Association of the European Society 
of Cardiology Working Group on PPCM defines it 
as an idiopathic cardiomyopathy presenting with 
heart failure secondary to left ventricular systolic 
dysfunction towards the end of pregnancy or in the 
months following delivery, where no other cause of 
heart failure is found.1 The left ventricle may not be 
dilated, but the ejection fraction has to be reduced 
below 45%.2 
PPCM may show resemblances to dilated cardio-
myopathy (DCM), in clinical presentation as well 
as in genetic background, and it is associated with 
maternal and fetal mortality and morbidity.2 Several 
pathophysiological mechanisms have been proposed 
to be involved in the aetiology of PPCM, such as 
autoimmunity, (viral) myocarditis, maladaptation 
to the hyperdynamic state of pregnancy, prolonged 
tocolysis and prolactin mediation.3–5 Also, the high 
variation in incidences between countries and conti-
nents suggests environmental factors to play a role.4
Patients are treated with conventional heart 
failure medication. Recently, bromocriptine has 
been discovered as having positive effects on 
the outcomes and can be added to standard heart 
failure treatment. While evidence on the effectivity 
and safety of bromocriptine is scarce, its use has 
been associated with a decrease in morbidity and 
mortality rates in patients with PPCM and higher 
rates of left ventricular recovery.6 Although full 
recovery does occur, a significant proportion of 
patients suffer from persistent systolic ventricular 
dysfunction.
The diagnosis of PPCM is difficult to make, as 
it is a diagnosis of exclusion, with a considerable 
overlap with other conditions. Especially in women 
who present with acute heart failure at the end of 
pregnancy or directly post partum, thorough inves-
tigations and intensive follow-up may often lead 
to alternative diagnoses. We describe four cases of 
patients with peripartum heart failure at our centre 
who were initially diagnosed with PPCM, but in 
whom a different diagnosis eventually emerged. We 
discuss the differential diagnosis, pathophysiolog-
ical mechanisms and the use of various diagnostic 
modalities.
Case A
This 31-year-old primigravida woman with a 
history of pulmonary embolism and multiple 
deep venous thrombosis during the index preg-
nancy was admitted to the obstetric department 
with pre-eclampsia with severe hypertension of 
160/100 mm Hg at 26 weeks of pregnancy. She 
had been taking vitamin K antagonists, which were 
switched to low-molecular-weight heparin, and she 
was treated with magnesium sulfate and intrave-
nous antihypertensive drugs. A primary caesarean 
section under general anaesthesia was performed 
at 30 weeks of pregnancy due to fetal distress, 
delivering a growth-restricted, premature girl of 
920 g. Postsurgery the mother developed severe 
postpartum haemorrhage with a total of 5000 mL 
blood loss, and treatment was complicated by her 
anticoagulation therapy. She received blood trans-
fusions and was discharged from the hospital with a 
haemoglobin level of 77.3 g/L. Three days later she 
was readmitted with complaints of fatigue, severe 
dyspnoea and fever. She had pleural effusion and 
thrombocytopaenia. She was later transferred to the 
cardiac intensive care unit (ICU) due to deteriora-
tion of her condition, and echocardiographic exam-
ination revealed severe left ventricular dysfunction 
with mild dilatation of the ventricles. ECG showed a 
sinus tachycardia with low voltages in the extremity 
leads and a QS pattern in V1–V3 (figure 1). Coro-
nary angiography showed normal coronary arteries 
and she was diagnosed with PPCM. She soon went 
into cardiogenic shock with high lactate levels, and 
when high dosages of inotropes could not stabi-
lise her extracorporeal membrane oxygenation 
(ECMO) was started. Heart failure medication was 
started, which stabilised her condition, and after 
15 days the ECMO could be removed. ECMO was 
complicated by cannula-related severe ischaemia of 
her right foot, which had to be amputated. She was 
transferred to a rehabilitation clinic after hospital 
discharge.
Because of the combination of multiple venous 
emboli, pre-eclampsia with proteinuria, pleural 
effusion and the thrombocytopaenia, the patient 
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was referred to an immunologist, who diagnosed her with anti-
phospholipid syndrome and systemic lupus erythematosus (SLE). 
Her last echocardiogram showed only a mild impairment of left 
ventricular function.
Case b
This 25-year-old primigravida woman with a history of child-
hood asthma and generalised anxiety disorder was admitted 
to a cardiology ward unit with progressive dyspnoea at 26 
weeks of pregnancy. Her ECG revealed several abnormalities 
(figure 2), and echocardiography showed a DCM with severe 
left and right ventricular dilatation and a left ventricular ejec-
tion fraction of about 10%–15% (figure 3A,B). She underwent 
emergency caesarean section the following day and was admitted 
to the ICU afterwards, where she was treated with heart failure 
medication and inotropes. Low-molecular-weight heparins were 
started because of a thrombus in the right ventricular outflow 
tract. ECMO was started due to refractory cardiogenic shock, 
and later a left ventricular assist device was implanted. There 
was no evidence of coronary artery disease. Due to severe confu-
sion and drowsiness in the ICU, a CT of the brain was made, 
showing generalised brain atrophy. Therefore, a metabolic origin 
was suspected. Myocardial biopsy showed a myopathic image 
suspected for mitochondrial storage disease due to excessive 
glycogen storage. Morbus Pompe and Fabry were ruled out and 
viral tests were negative, as were autoimmune and paraneoplastic 
syndromes. Quadriceps femoris muscle biopsy showed a myop-
athy without specific characteristics. Blood and urine tests were 
performed, as well as genetic tests. Plasma carnitine was strongly 
elevated and a diagnosis of succinyl-CoA ligase deficiency was 
Figure 1 ECG of patient A at admission. There was a noted sinus tachycardia with low voltages in the extremity leads and a QS pattern in V1–
V3. aVR, augmented vector right; aVL, augmented vector left; aVF, augmented vector foot. 
Figure 2 ECG of patient B at diagnosis. Sinus rhythm with notched high-amplitude P-waves, QRS of 120 ms, negative repolarisation in the inferior 
and lateral leads, and QS complex in V1. aVR, augmented vector right; aVL, augmented vector left; aVF, augmented vector foot. 
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suspected, but could eventually not be confirmed as the results 
of further tests and analyses were inconclusive. No known muta-
tions in the DCM genes were found, and the diagnosis of PPCM 
remained the working diagnosis. Her prematurely born son was 
diagnosed with (congenital) hypertrophic cardiomyopathy. One 
year later, the patient underwent a cardiac transplantation and is 
currently doing relatively well.
Case C
This 36-year-old woman with a history of unspecified palpi-
tations and a family history of sudden cardiac death, who 
had once been assessed by a cardiologist because of suspected 
long-QT syndrome in her infant daughter, was admitted to the 
cardiology ward unit with complaints of dyspnoea and chest 
pain, 4 months after giving birth to her third child. Her N-ter-
minal prohormone of brain natriuretic peptide (NT-proBNP) 
was markedly elevated, and echocardiography revealed a DCM 
with a left ventricular ejection fraction of 15% and moderate to 
severe tricuspid insufficiency and a moderate to severe mitral 
insufficiency. She was diagnosed with PPCM and was treated 
with heart failure medication on which she slowly recovered. 
She was discharged home and seen by a cardiologist for regular 
follow-up. A 24-hour Holter ECG showed frequent, non-sus-
tained ventricular tachyarrhythmias, and as part of her outpatient 
follow-up an MRI scan of her heart was made, which showed 
distinct tubular dilatation of the right ventricle, with less distinct 
dilatation of the left ventricle (figure 4). Hypokinesia was most 
prominent in the right ventricle and there was severe tricuspid 
insufficiency. A diagnosis of arrhythmogenic right ventricular 
cardiomyopathy (ARVC) was made and a prophylactic internal 
cardiac defibrillator was implanted. Genetic tests revealed no 
known mutation. Her left ventricular function has almost fully 
recovered, but her right ventricular function remains moderately 
impaired.
Case d
This 26-year-old primigravida woman in labour with an unre-
markable medical history was urgently admitted to the obstetrics 
department with failure to progress in the second stage and the 
suspicion of an intrauterine infection. She underwent an emer-
gency caesarean section, which was complicated by a severe 
postpartum haemorrhage with a blood loss of 2 L. She was treated 
with sulprostone and intravenous fluids and a blood transfusion, 
immediately after which she became severely dyspnoeic. Chest 
X-rays showed congestion, and echocardiography revealed 
severe left ventricular dysfunction with an estimated ejection 
fraction of 15% and only moderate wall motility in the basal 
septal region. There were no signs of ischaemia or coagulopathy 
(thereby excluding amniotic fluid embolism). The diagnosis of 
PPCM was suspected and she was intubated and transferred to 
the ICU, where she was treated with conventional heart failure 
medication. She could be extubated very quickly after initiation 
of therapy, and repeat echocardiography showed normalisation 
of left ventricular function with normal ventricular dimensions 
within a few days. She had experienced the caesarean section as 
Figure 3 (A) Parasternal long axis on echocardiogram of patient B at diagnosis. The LVEDD was 76 mm. (B) Four-chamber apical view of patient 
B at diagnosis. Biventricular dilatation with severely impaired right and left ventricular function. Severe mitral regurgitation. BPM, beats per minute; 
LVEDD, left ventricular end diastolic diameter. 
Figure 4 Four-chamber MRI view of patient C. Distinct tubular 
dilatation of the right ventricle (RV) with dyskinesia, impaired RV 
ejection fraction (34%) and elevated RV end-diastolic volume index 
(132.4 mL/min). Also oedema and late enhancement in the wall of the 
right ventricle. 
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very traumatic and has visited a psychologist to help her cope. In 
the outpatient clinic, the question rose whether she had suffered 
from PPCM or whether her acute heart failure was caused by a 
takotsubo cardiomyopathy. The urgent and complicated char-
acteristics of the delivery, as well as the echocardiographic 
images of akinesia affecting the whole ventricle except the basal 
segments and the very rapid recovery of the ejection fraction, are 
suggestive of a takotsubo cardiomyopathy rather than a PPCM. 
She returned to the cardiologist a few years later with the wish 
to become pregnant again. Due to her recovered left ventricular 
function, there were no objections to a subsequent pregnancy 
and she has had several uncomplicated pregnancies since. Her 
left ventricular function has remained normal to date.
dIsCussIon
We have described four women who presented during pregnancy 
or in the early postpartum period with signs of heart failure and 
echocardiographic signs of severely impaired left ventricular 
function. The peripartum onset makes the diagnosis of PPCM 
likely; however, features of the patients’ history and the results 
of specific investigations including histology suggested alterna-
tive diagnoses.
Myocarditis in SLE is usually asymptomatic, and while cardiac 
problems in SLE are often related to coronary disease, which 
was ruled out in our patient, lupus myocarditis without coro-
nary involvement is not uncommon.7 Moreover, the incidence 
of non-coronary cardiac disease in patients with SLE is relatively 
common, certainly when compared with the incidence of PPCM 
in the general population, and this is an important consider-
ation in making a diagnosis in such a complex patient.7 Also, 
lupus flares as a result of pregnancy are not uncommon. The 
distinction between PPCM and SLE-related or other myocar-
ditis is challenging, but very important with respect to subse-
quent pregnancies.8 In contrast to lupus myocarditis, PPCM has 
a high recurrence rate and persisting ventricular dysfunction 
is common, both make the management of future pregnancies 
challenging.8
Mitochondrial myopathies can be isolated to skeletal muscle, 
but can also affect cardiac muscle, presenting with a wide range 
of clinical problems.9 As with other metabolic disorders, mito-
chondrial myopathies can present during periods of increased 
physiological stress, such as pregnancy and delivery,9 with acute 
heart failure or encephalopathy. In our patient, the extensive 
cerebral atrophy was remarkable, as well as the marked cardiac 
hypertrophy in her newborn son. While she still remains without 
definitive diagnosis, a mitochondrial problem would be consis-
tent with the clinical picture.
Other forms of cardiomyopathy, such as ARVC as diagnosed in 
our patient, have been misdiagnosed as PPCM when presenting 
in the peripartum period. In an article from 2011, mutations 
in the titin (TTN) gene were associated with ARVC, the same 
mutation as reported in both DCM and PPCM.10 11 There are 
numerous case reports describing the first presentation of these 
cardiomyopathies during the peripartum period, consistent with 
a common aetiological pathway.
In PPCM, many pathophysiological mechanisms have been 
suggested, but it is unlikely that there is one single mecha-
nism. With respect to the pregnancy-associated aetiologies, 
many advances have been made in the angiogenic imbalance 
theory.12 13 During pregnancy, the placenta secretes antiangio-
genic factors, such as soluble fms-like tyrosine kinase-1 (sFLt-1). 
This factor is important in the regulation of blood vessel forma-
tion in various tissues, and has been linked to (pre-)eclampsia 
and heart failure.14 15 sFLt-1 causes ventricular dysfunction, the 
extent of which correlates with the serum quantity of sFLt-1, 
and it is known that women with PPCM have extremely high 
circulating levels.13 The profound systolic impairment found 
in women with PPCM is mimicked in mice lacking PGC-1α 
(peroxisome proliferator-activated receptor gamma coactivator 
1-alpha, a powerful regular of angiogenesis) after administration 
of exogenous sFLt-1, suggesting an aetiological role for excess 
antiangiogenic factors in the peripartum period.16
Another hypothesis that has been repeatedly proposed 
within the recent literature is the prolactin and oxidative stress 
theory.1 4 Late in pregnancy, high levels of low-density lipopro-
tein-cholesterol are present, which are susceptible to oxidation. 
Oxidative stress in pregnancy in combination with high levels 
of prolactin at the end of pregnancy can result in the forma-
tion of the 16 kDA form of prolactin, which is both angiostatic 
and proapoptotic, and can impair endothelial function resulting 
in cardiac inflammation.2 4 17 High prolactin levels are inevi-
table in pregnancy, thus a pathophysiological role in PPCM is 
very possible; however, it might not be exclusive to pregnancy. 
Hyperprolactaemia is present in about 25% of non-pregnant 
patients with heart failure and also seems to be a predictor of 
prognosis in advanced congestive heart failure in non-pregnant 
patients.17–20
The introduction of bromocriptine as treatment for PPCM is 
based on the theory of prolactin-mediated endothelial dysfunc-
tion; it seems to have beneficial effects on morbidity and 
mortality and is associated with higher rates of left ventricular 
recovery.6 However, in women taking bromocriptine for the 
prevention of breast engorgement in the postpartum period, 
there was an increased incidence of myocardial infarction and 
other thromboembolic events.21 22 Therefore, concomitant anti-
coagulation therapy is strongly recommended.4 22 Outside of 
pregnancy, bromocriptine also reduces cardiovascular mortality 
in other conditions.23 Bromocriptine has been shown to lower 
plasma norepinephrine levels and to induce vasodilation acting 
via dopaminergic receptors in the vessel wall, suggesting alter-
native mechanisms for its beneficial effects independent of any 
effect on prolactin levels.
Due to PPCM being a diagnosis of exclusion and the overlap 
with other syndromes, it is possible that many cases of PPCM 
are missed. On the other hand, the haemodynamic stress of 
pregnancy can reveal undiagnosed cardiac conditions such as 
DCM, or can give rise to conditions such as takotsubo cardio-
myopathy, which could also mimic PPCM. It can also be hard to 
distinguish PPCM from pre-eclampsia and eclampsia, especially 
when they are complicated by pulmonary oedema. Furthermore, 
drugs administered for postpartum haemorrhage, like prosta-
glandin analogues, can cause coronary spasms and other severe 
cardiovascular reactions, mimicking PPCM.24 Consequently, 
many women diagnosed with PPCM, when they present with 
(acute) heart failure during pregnancy or in the postpartum 
period, may have their diagnosis changed after additional tests. 
Thus, the importance of re-evaluation of a diagnosis of PPCM is 
clear. Figure 5 depicts a flow chart for the management of previ-
ously healthy women with a peripartum onset of heart failure, 
in which re-evaluation of the working diagnosis is incorporated, 
including a minimal work-up package for diagnostics.
Around two-thirds of women with PPCM present 
post partum,25 a finding that can therefore also be sugges-
tive of the diagnosis: in the case of a previously discharged 
healthy women presenting with heart failure a few months 
after delivery, the diagnosis of PPCM becomes more prob-
able. However, the patients we describe in this paper 
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highlight that, in some cases, especially when there are atyp-
ical symptoms or an onset before 36 weeks of gestation, an 
alternative diagnosis is more likely. Table 1 gives an over-
view of various atypical presentations of peripartum-onset 
acute heart failure with corresponding differential diag-
noses. Overall in the literature, about 15% of patients with 
PPCM have a genetic mutation known to be associated 
with DCM. This may seem to be lower than expected, but 
a genetic mutation is found in only 30% of DCM cases. 
Although data are scarce, there are an increasing number 
of reports available in the literature in which a connection 
between PPCM and familial DCM is suggested. In one Dutch 
study, 90 families with familial DCM were studied, looking 
for evidence of PPCM; in addition, patients with PPCM and 
their first-degree relatives were genetically screened. The 
authors concluded that at least a proportion of PPCM cases 
are the initial presentation of familial DCM.26
This identification of pathogenic mutations in other 
familial cardiomyopathies further highlights the possibility 
that many cases of PPCM might be due to genetic DCM 
revealed for the first time by the stress of pregnancy. Also, 
the higher incidence in specific ethnic groups and in defined 
areas of the world suggests a role of environmental and/
or genetic factors.4 Furthermore, the diagnosis of takot-
subo cardiomyopathy has to be considered in the event of 
a traumatic or complicated delivery, as well as in the crit-
ically ill (severe pre-eclampsia or eclampsia, severe post-
partum haemorrhage) or postoperative patient (caesarean 
delivery).27
Due to the difficulties in diagnosing heart failure mani-
festing during pregnancy or in the postpartum period and 
the limited availability of broad genetic tests, it is very likely 
that patients with genetic forms of DCM and other cardio-
myopathies have been included in the published studies 
on PPCM over the past decades. This has the potential to 
fuel a cycle of overdiagnosis and ever increasing incidence 
of what might be a relatively rare condition. For example, 
the increases in incidence of PPCM in the USA (from 1 per 
4350 in 1990–1993 to 1 per 2229 in 2000–2002)28 might be 
attributable to increased awareness of the condition, but also 
to (subsequent) overdiagnosis.
It is probable that a collection of pregnancy-related 
factors, which include haemodynamic stress and high 
prolactin levels, combined to varying degrees with an under-
lying genetic predisposition for cardiomyopathy, result in 
the prepartum or immediate postdelivery onset of heart 
failure, with the exact importance of each factor varying 
from case to case. As the exact pathophysiology remains 
largely unknown and as it displays very similar clinical, 
demographical and genetic characteristics to other forms of 
Figure 5 Flow chart for management of peripartum onset heart failure. ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated 
cardiomyopathy; PPCM, peripartum cardiomyopathy; HCM, hypertrophic cardiomyopathy; Hb, hemoglobin; Ht, hematocrit; NYHA, New York Heart 
Association.
Table 1 Differential diagnosis of peripartum cardiomyopathy-atypical presentations of acute heart failure in the peripartum period
Atypical presentation of peripartum-onset heart failure differential diagnosis
Presentation before 36th week of pregnancy Pre-existing (dilated) cardiomyopathy, pulmonary oedema secondary to (pre-)eclampsia, myocarditis, autoimmune 
disease-related myocardial dysfunction (systemic lupus erythematosus, antiphospholipid syndrome), metabolic 
myopathy, ischaemic heart disease (eg. spontaneous coronary artery dissection).
Presentation after 6 months postdelivery Familial, pre-existing (dilated) cardiomyopathy, myocarditis.
Presentation during complicated or traumatic delivery Amniotic fluid embolism, takotsubo cardiomyopathy.
Acute presentation immediately post partum after 
misoprostol administration
Coronary artery spasm with subsequent cardiac dysfunction, amniotic fluid embolism.
Primary presentation with (tachy)arrhythmias or (aborted) 
sudden cardiac death
Arrhythmogenic right ventricular cardiomyopathy, catecholaminergic polymorphic ventricular tachycardia, mitral 
valve prolapse.
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cardiomyopathy, it may be defensible to regard PPCM as a 
syndrome, rather than a distinct diagnosis—a syndrome of 
peripartum heart failure of unknown origin, characterised 
by a reduced left ventricular ejection fraction accompanied 
by symptoms of heart failure, elicited by peripartum-induced 
changes in haemodynamic, hormonal and/or homeostatic 
systems, in previously healthy women, women with a pre-ex-
istent (unknown) condition or women with a predisposition 
for developing (dilated) cardiomyopathy. As such, it remains 
a diagnosis of exclusion or a diagnosis made in the early 
stages of the disease, when more definite answers are still 
being sought.
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